Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLONAZEPAM

All products: general benefit

Other products in the same Health Canada class (N03A) — coverage varies; not interchangeable

  • Carbamazepine (Tegretol): general benefit, Limited Use, Not a benefit, Listing status unconfirmed
  • Divalproex (Epival): general benefit
  • Ethosuximide (Zarontin): general benefit
  • Lamotrigine (Lamictal): general benefit
  • Phenytoin diphenylhydantoin (Dilantin-30 Suspension): general benefit
  • Phenytoin diphenylhydantoin (Dilantin): general benefit, Limited Use 481, 657

14 more in the class list below

Rivotril · DIN 00382825 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Rivotril · DIN 00382825 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 2023-01-31 · brand RIVOTRIL · ATC N03AE01 CLONAZEPAM · form Tablet · route Oral · ingredients CLONAZEPAM 0.5 MG · company Cheplapharm arzneimittel gmbh · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Ministry pays: $0.0418 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2568 · Verify on the e-Formulary ↗ (DIN 00382825)

Source record
DIN 00382825: Rivotril Raw flags: sec3=Y Item: 281200032; group id 426; item number 1059; lccId None; manufacturer id HLR Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.2906; ministry $0.0418 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00382825 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2568
Interchangeable products
Apo-Clonazepam · DIN 02177889 · $0.0418 PMS-Clonazepam · DIN 02048701 · $0.0418 PMS-Clonazepam-R · DIN 02207818 · $0.0418 Teva-Clonazepam · DIN 02239024 · $0.0418
Shortage status: resolved shortage (ended 2023-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00382825
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L

VALPROIC ACID

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS RIVOTRIL (clonazepam) is indicated for use:  alone or as an adjunct in the management of myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut syndrome).  in patients with absence spells (petit mal) who have failed to respond to succinimides. Up to nearly one-third of the patients in some studies have shown a loss of anticonvulsant activity, often within the first three months of administration of RIVOTRIL. In some cases, dosage adjustment may re-establish efficacy. RIVOTRIL (clonazepam) is a benzodiazepine, available under the “Targeted” Schedule of the Controlled Drugs and Substances Act (CDSA IV) of Health Canada. 1.1 Pediatrics (<18 years of age) See 4.2 Recommended Dose and Dosage Adjustment, Pediatrics; 7.1.3 Pediatrics; and 10.3 Pharmacokinetics, Special Populations, Pediatrics. 1.2 Geriatrics (>65 years of age) Evidence from clinical studies and experience suggests that the use in the geriatric population is associated with differences in safety and effectiveness. See 7.1.4 Geriatrics; and 4.2 Recommended Dose and Dosage Adjustment, Geriatrics. https://pdf.hres.ca/dpd_pm/00065630.PDF PM date: April 28, 2022 Source product: RIVOTRIL; DIN 00382825; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.